Registry of Primary Lung Tumours in Ain Shams Hospitals

Abstract Background Bronchogenic carcinoma is a malignant lung tumor characterized by uncontrolled cell growth in tissues of the lung. This growth can spread beyond the lung by the process of metastasis into nearby tissue or other parts of the body. Most cancers that start in the lung, known as primary lung cancers, are carcinomas, The two main types are small-cell lung carcinoma (SCLC) and non- small-cell lung carcinoma (NSCLC). Aim of the Study Register cases of primary lung tumors presented to Ain shams university hospital during period from June 2018 to June 2019 and to follow up their response to different lines of treatment and to assess delay time between diagnosis and start of treatment. Patients and Methods This study is an observational, analytical and retrospective study, conducted upon 95 cases of primary lung tumor cases presented to Ain Shams University Hospital _oncology chest clinic. Results The main age of our studied population ranging from 17 to 66 years old in cases diagnosed as small cell lung cancer (SCLC), from 30 to 81 years old in cases diagnosed as non small cell lung cancer(NSCLC), eight out of nine cases diagnosed as SCLC were males, sixty six out of 86 NSCLC cases were males, about 66.7% of SCLC cases & 57% of NSCLC were smokers, forty four percent of SCLC presented with performance score 2, while 48.8% of NSCLC presented with performance score 1, Out of 86 cases of non small cell lung cancer 54 were adenocarcinoma, 27 were squamous cell carcinoma, 4 cases were large cell lung cancer and 1 case was mucoepidermoid carcinoma. Dyspnea was the main symptom in SCLC cases (6 cases out of 8). Fibreoptic bronchoscopy was the diagnostic tool in 33.3% of SCLC cases, 29.1% of NSCLC cases. In non small cell lung cancer, US guided biopsy took the second hand after fibreoptic bronchoscopy by 25.6%, Most of cases were stage 4, 77.8% in small cell carcinoma, 80.2% in non small cell lung cancer. SCLC received Gemcitabine/carboplatin in 33.3% of cases, 22.2% of cases received palliative radiotherapy as first line treatment.11.1% of them received definitive radiotherapy as second line treatment.In NSCLC, 25.6% of cases treated with Gemcitabine/carboplatin, 17.4% received palliative radiotherapy.In NSCLC 36% of cases presented with dyspnea then chest pain 22%.The relation between delay time and prognosis as regard disease progression is non significant similar to the relation between delay time from definitive diagnosis to start of treatment)and stage at time of diagnosis. Unlikely, the inverse relation between delay time and ECOG(Eastern Cooperative Oncology Group Performance status) in both small and non small cell lung cancer. Conclusion The relation between delay time and prognosis is non significant similar to the relation between delay time and stage at time of diagnosis. Unlikely, the inverse relation between delay time and ECOG in both small and non small cell lung cancer.